4 results match your criteria: "Gregorio Marañon Universisty Hospital.[Affiliation]"
A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research.
Eur J Cancer
January 2025
Center for Dermato-oncology, Department of Dermatology, Eberhard Karls University of Tübingen, 72076 Tübingen, Germany.
Background: Over the past decade, PD-1-based immune checkpoint inhibitors (ICI) and targeted therapies (TT) with BRAF and MEK inhibitors transformed melanoma treatment. Both are widely used in the adjuvant setting. However, for patients with a BRAF V600 mutation, the optimal adjuvant therapy remains unclear due to the lack of head-to-head comparison studies.
View Article and Find Full Text PDFAggressive Late Recurrence of a Calcifying Epithelial Odontogenic Tumor: Surgical Refinements Based on New Technologies.
J Craniofac Surg
July 2024
Department of Oral and Maxillofacial Surgery, Gregorio Marañon Universisty Hospital.
A calcifying epithelial odontogenic tumor is a rare, benign odontogenic neoplasm. Surgical treatment is the option, and late recurrence is very rare. Radiologically, the lesions are commonly present scattered calcifications.
View Article and Find Full Text PDFInvasive Treatment Strategy in Adults With Frailty and Non-ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of a Randomized Clinical Trial.
JAMA Netw Open
March 2024
Cardiology Department, University Hospital of Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
Article Synopsis
- The MOSCA-FRAIL trial investigated treatment approaches for frail patients (aged ≥70) with non-ST-segment elevation myocardial infarction (NSTEMI) and found no significant difference in health outcomes after one year between invasive and conservative strategies.
- Following extended follow-up until January 2023, the analysis of 167 patients indicated similar survival times and readmission rates, revealing that neither treatment significantly outperformed the other.
- Overall, while initial outcomes suggested that invasive treatment might lead to shorter survival in the first year, the long-term results demonstrated inconclusive differences, highlighting the need for personalized treatment decisions in frail older adults.
Effect of Routine Invasive vs Conservative Strategy in Older Adults With Frailty and Non-ST-Segment Elevation Acute Myocardial Infarction: A Randomized Clinical Trial.
JAMA Intern Med
May 2023
Cardiology Department, University Hospital of Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
Article Synopsis
- This study is the first randomized clinical trial to compare invasive versus conservative treatment strategies for frail, older patients (≥70 years) with non-ST-segment elevation acute myocardial infarction (NSTEMI).
- Conducted across 13 hospitals in Spain from 2017 to 2021, it included 167 patients and measured primary outcomes like days alive and out of the hospital (DAOH) and the rates of cardiac-related complications.
- Results showed that while conservatively managed patients had slightly more DAOH (312 days) compared to those managed invasively (284 days), the difference was not statistically significant, and no major differences in mortality were found between the two groups. *